Compare Twist Bioscience Corp (TWST) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Waste Management, Inc. — how do they compare? Twist Bioscience Corp trades at $160 (market cap $10.08B), while Waste Management, Inc. trades at $208.73 (market cap $83.98B). The key difference: Waste Management, Inc. is far larger — about 8.3× Twist Bioscience Corp's market cap, and Waste Management, Inc. pays a 1.8% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Waste Management, Inc. for 130 Days on average.
| TWST | WM | |
|---|---|---|
Market Cap | $10.08B | $83.98B |
Volume | 4,229,037 | 2,182,180 |
Sector | Health | Industrials |
52-Week High | $205.00 | $246.51 |
52-Week Low | $25.45 | $196.77 |
Typical Hold Time | 27 Days | 130 Days |
Enterprise Value | $10.01B | $106.78B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
WM trades at $208.94, up 0.51% today, with a bearish technical signal but strong fundamentals including 11.12% net income margin and 29.83% ROE. Recent earnings show beats in Q1 and Q2 2026, while Q4 2025 missed estimates. Revenue grew to $25.20B in 2025, and cash flow from operations remains robust at $6.04B. Analyst sentiment is positive with 54% buy ratings and no sell recommendations.
The outlook is supported by steady revenue growth and high profitability, but risks include elevated debt levels and competitive pressures. The stock's valuation at a P/E of 29.72 may limit near-term upside, though institutional backing and dividend payments provide stability. Investors should weigh solid cash generation against debt concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
